| Literature DB >> 35740618 |
Navid Sobhani1, Richard Chahwan2, Raheleh Roudi3, Rachel Morris4, Stefano Volinia5, Dafei Chai1, Alberto D'Angelo6, Daniele Generali7.
Abstract
For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been shown to play crucial roles in shaping the activity of cells. An extraordinary number of studies has shown that ncRNAs represent an extensive and prevalent group of RNAs, including both oncogenic or tumor suppressive molecules. Henceforth, various clinical trials involving ncRNAs as extraordinary biomarkers or therapies have started to emerge. In this review, we will focus on the prognostic and diagnostic role of ncRNAs for breast cancer.Entities:
Keywords: biomarkers; breast cancer; diagnostic; non-coding RNA; prognostic
Year: 2022 PMID: 35740618 PMCID: PMC9221286 DOI: 10.3390/cancers14122952
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575